The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 co-agonist retatrutide. While both https://ihannayfey014368.nico-wiki.com/2040734/glp_3_retatrutide_a_comparative_analysis